STOCKHOLM (EGMN) – When European drug regulators called for a study to push the safety profile of the sympathomimetic weight-loss drug sibutramine to its limit, sibutramine failed the test.
STOCKHOLM (EGMN) – When European drug regulators called for a study to push the safety profile of the sympathomimetic weight-loss drug sibutramine to its limit, sibutramine failed the test.